Italy's Diasorin confirms 2026 target, sees 6-8% sales growth until 2030 (updated)

DiaSorin SpA

20/05/2026 10:58

Adds background in paragraph 3, key growth drivers in paragraph 4

May 20 (Reuters) - Italy's Diasorin DIAS.MI confirmed its 2026 guidance and outlined a new 2026-2030 business plan ahead of a presentation to investors on Wednesday.

The medical diagnostics firm said it expected average revenue growth of 6% to 8% per year at constant exchange rates between 2026 and 2030. That is slightly above the 5% to 6% growth guidance for 2026.

The 2026-2030 strategic plan is being closely watched by investors looking for signs of a rebound after a November guidance cut sent Diasorin's shares to an over eight-year low.

The company said continuous growth in the U.S. and specialty menu expansions in more than 20 new high-value clinical segments would be among the key growth drivers for its immunodiagnostics business.

"The 2026-2030 Plan reflects our ambition to strengthen Diasorin’s positioning as a leader in specialty diagnostics, leveraging the Group’s different business lines through the introduction of new tests and cutting-edge technological platforms,” CEO Carlo Rosa said in a statement.

(Reporting by Anna Uras, editing by Milla Nissi-Prussak)

((Anna.Uras@thomsonreuters.com;))